Abstract | OBJECTIVES: METHODS: A multicentric, randomized open trial was conduced in 595 patients by general practitioners to determine acceptability, efficacy and tolerance of lomefloxacine 400 mg in a once a day dose given for three days compared with a once-a-day 800 mg dose of pefloxacin for the treatment of lower urinary tract infection in women. RESULTS: The delay to symptom relief was greater than 24 hours in both treatment groups. Symptom relief was observed after treatment onset in only 23% of the patients. Clinical success rate at day 14 was 94.2% for lomefloxacin and 95.7% for pefloxacin. The rates of bacteriological eradication were 90.6% and 92.8% respectively with no significant difference. Adverse events were reported in 27.1% and 33.3% of the patients respectively, digestive disorders ( abdominal pain, nausea) and neurosensorial disorders ( headache, dizziness) predominated. There was no serious adverse event. The incidence of adverse events related to the treatment according to the investigator was smaller with lomefloxacin (16.1%) than with pefloxacin (23.5%) (p = 0.026). CONCLUSION: Acceptability, assessed at day 14, was not significantly different between the two treatment groups. Lomefloxacin was the only antibiotic currently authorized for use in a three-day regimen for the treatment of lower urinary tract infections.
|
Authors | J Guibert, M H Capron, A Giacomino |
Journal | Presse medicale (Paris, France : 1983)
(Presse Med)
Vol. 25
Issue 28
Pg. 1271-5
(Sep 28 1996)
ISSN: 0755-4982 [Print] France |
Vernacular Title | Traitement de la cystite aiguë non compliquée de la femme: loméfloxacine versus péfloxacine. |
PMID | 8949786
(Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Anti-Infective Agents
- Fluoroquinolones
- Quinolones
- Pefloxacin
- lomefloxacin
|
Topics |
- Acute Disease
- Adult
- Anti-Infective Agents
(therapeutic use)
- Cystitis
(drug therapy)
- Family Practice
- Female
- Fluoroquinolones
- Humans
- Middle Aged
- Pefloxacin
(therapeutic use)
- Quinolones
(therapeutic use)
|